Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard, Tae Min Kim, Julien Mazières et al. · The Lancet Oncology · 2016
Cited by 454 works. doi:10.1016/s1470-2045(16)00077-2
Authors
- David Planchard
- Tae Min Kim
- Julien Mazières
- Élisabeth Quoix
- Gregory J. Riely
- Fabrice Barlési
- Pierre-Jean Souquet
- Egbert Frederik Smit
- Harry J.M. Groen
- Ronan Joseph Kelly
- Byoung Chul Cho
- Mark A. Socinski
- Lini Pandite
- Christine Nase
- Anthony Michael D'amelio
- Bijoyesh Mookerjee
- C. Martin Curtis
- Bruce Evan Johnson
References
- Mutations of the BRAF gene in human cancer
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Cancer statistics, 2015
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF